key: cord-0999845-c50bxku8
authors: Jayaram, Aswathi; Buhimschi, Irina A.; Aldasoqi, Hayfaa; Hartwig, Julie; Owens, Thomas; Elam, Gloria L.; Buhimschi, Catalin S
title: Who Said Differentiating Preeclampsia From COVID-19 Infection Was Easy?
date: 2021-07-24
journal: Pregnancy Hypertens
DOI: 10.1016/j.preghy.2021.07.248
sha: d1c0d34f86f15709caf74962e60cbf0b9ba845d3
doc_id: 999845
cord_uid: c50bxku8

nan

Differentiating preeclampsia from clinical imitators during pregnancy (e.g. fatty liver disease, lupus, chronic hypertension, kidney disease) has never been easy. Recent reports suggest COVID-19 infection is an additional preeclampsia imitator. 1, 2 We sought to identify clinical phenotypic features with potential to discern COVID-19 from preeclampsia on clinical grounds alone.

From April to November 2020, 1,418 pregnant women at >20 weeks' gestational age were screened for SARS-CoV-2 infection at University of Illinois at Chicago's Labor and Delivery

Unit. Demographic and clinical data including the need for preeclampsia work-up were prospectively collected and entered into a database. To determine if COVID-19 modifies the severity of clinical symptoms triggering the need for preeclampsia workup, we designed two scores, one corroborating the clinical symptomatology (clinical severity score) and the other summing the presence or absence of abnormal laboratory test results (laboratory severity score) as previously described. 3 Pregnancy hypertensive disorders were defined using recognized clinical criteria. 4 Final diagnoses were considered confirmed if specifically documented after the work-up as preeclampsia with or without severe features, gestational hypertension or chronic hypertension and supported by the clinical rationale of the managing providers. The Institutional Review Board concluded this analysis was not human subject research.

PREGHY-D-21-00177 Revision 1

Within the study period 75 mothers tested SARS-CoV-2 positive for a prevalence of 5.2% Table 1 . The frequency of a clinically confirmed diagnosis of preeclampsia was similar in the groups that underwent preeclampsia work-up irrespective of COVID-19 positivity. However, the frequency of a final diagnosis of gestational hypertension was lower among COVID-19 positive women with more of these women having negative work-up results. Overall, a diagnosis of COVID-19 during index pregnancy did not appear to impact on the severity of clinical symptoms triggering preeclampsia work-up, with no clinical symptom or sign being identified more often in the COVID-19 positive group (Table 2) . A positive SARS-CoV-2 test result was not associated with a higher need for anti-hypertensive or magnesium therapy during pregnancy.

COVID-19 infection did not significantly alter the platelet count, kidney or liver function tests and laboratory scores among the patients in this study. Results maintained when analysis was restricted to patients screened for COVID-19 infection and evaluated for preeclampsia during the same episode of care. PREGHY-D-21-00177 Revision 1

Recent reports have raised the question whether the SARS-CoV-2 virus selectively targets the vascular endothelium and kidneys to explain the high frequency of newly diagnosed hypertension and kidney dysfunction associated with COVID-19 infection. 5, 6 However, for pregnant patients any newly identified hypertension generates concern due to overlapping symptomatology with gestational hypertension and preeclampsia making differentiation between two condition impossible on clinical grounds alone. Our study demonstrates that women who are positive for COVID-19 undergo work-up for preeclampsia more frequently due to clinical uncertainty but do not seem to have a higher frequency of symptomatology or laboratory abnormalities than expected for the COVID-negative group with preeclampsia. To differentiate between newly induced COVID-19 hypertension which is likely transitory and preeclampsia and to diminish unnecessary laboratory testing and hospitalization more specific molecular markers for preeclampsia are needed. 

Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study

Can COVID-19 in pregnancy cause pre-eclampsia?

Antenatal corticosteroids impact the inflammatory rather than the antiangiogenic profile of women with preeclampsia

Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy

Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19

COVID-19 and its impact on the cardiovascular system

Support from this study was from the Quality Improvement Initiative Program of the Department of Obstetrics & Gynecology, University of Illinois at Chicago. The funding source had no role in study design, data analysis, writing of the report, or decision to submit for publication. PREGHY-D-21-00177 Revision 1